Why Is NVO Stock Falling Pre-Market Today?
Synopsis
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.
Novo Nordisk AS (NVO) shares fell more than 10% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.
Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.
Retail sentiment on Stocktwits around Novo Nordisk trended in the ‘extremely bearish’ territory at the time of writing.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.